The problem is that some OSA patients who would benefit from Continuous Positive Airway Pressure (CPAP) machines can’t or won’t use it because they find it uncomfortable, even though CPAPs have proven to be very effective in increasing oxygen flow and reducing apneic events that result in snoring.
But thankfully, medical advances are happening almost weekly, and so it is with sleep apnea diagnosis and treatment. One study that has me particularly excited recently appeared in the New England Journal of Medicine. It was also written about in The New York Times by Catherine Saint Louis.
Inspire Medical Systems, based in Minneapolis, Minnesota, has developed a something called the neurostimulator to treat OSA. The pacemaker-like device is surgically implanted in the chest, and at night, the device sends regular electric impulses to a nerve inside the jaw. These electric impulses cause the tongue to move forward during inhalation, opening up the airway, improving air flow and reducing breathing pauses.
Inspire Medical Systems funded a study to test the neurostimulator. Doctors surgically implanted remote-controlled neurostimulators in 126 patients, and activated them at night as the patients slept. After one year, patients experienced a marked decline in breathing pauses—from 29.3 episodes per hour to nine per hour, on average. Dangerous drops in blood oxygen levels also declined, from 25.4 per hour to 7.4 per hour, on average. At one year, 86 percent of patients said they use the neurostimulator on a daily basis, and two of the 126 patients stopped using in at night. Sleep apnea worsened in about 20 patients using the device, but doctors are not yet sure why.
The second phase also showed indications that the neurostimulator is effective in OSA treatment. In 46 patients who showed that the treatment was helping their OSA after one year, some were told to continue with the therapy or have it withdrawn for one week. Not surprisingly, those who continued the neurostimulator therapy showed little change in the number of breathing pauses per hour or drops in blood oxygen levels. But in the patients no longer using the therapy, the number of breathing pauses increased sharply, from 7.6 per hour to 25.8 per hour, on average. And the episodes of blood oxygen level drops rose from 6 per hour to 23 per hour, on average.
While more research and study is needed, the results are truly encouraging that upper airway neurostimulator therapy may soon be an effective and welcome alternative for OSA treatment, especially for those patients who have difficulty with CPAP masks and machines.
Read the full article entitled, “Upper-Airway Stimulation for Obstructive Sleep Apnea” in The New England Journal of Medicine.
